Inhibiting the expression or activity of BACE1 exhibits promising effects in attenuating cognitive deficits and other AD‐related pathology in both animal models and the early phases of clinical trials (Cummings et al., 2020; Deng et al., 2016; Hu et al., 2018; Peters et al., 2018). The gene discussed is BACE1; the disease is Alzheimer disease.